Novocure (NASDAQ: NVCR) today reported financial results for the quarter and full year ended December 31, 2025. Novocure is a global oncology company working to extend survival in some of the most ...

Novocure (NASDAQ: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua® through the country’s National Health Insurance coverage.

Novocure (Nasdaq:NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare approved reimbursement for its ...

Management issued guidance of $675 million to $705 million in net revenue for 2026, assuming Optune Gio net revenue growth in the low to mid-single digits and $15 million to $25 million in net revenue ...

Non-GBM Product Revenue Expectation -- Expected contribution of $15-$25 million in 2026, compared to $10 million in 2025, ...

On Tuesday, NovoCure announced that long-serving CEO Asaf Danziger is stepping down, effective Jan. 1, 2025. He will be replaced by the biotech company's current CFO, Ashley Cordova. Following the ...

The market expects NovoCure (NVCR) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook ...

For the first quarter, NovoCure recorded net revenue that was just shy of $155 million. That was a nearly 12% improvement over the same period of 2024. Compounding that, the biotech managed to narrow ...

The "NovoCure Ltd (NVCR) - Product Pipeline Analysis, 2025 Update" company profile has been added to ResearchAndMarkets.com's offering. This report is a source for data, analysis, and actionable ...

The Swiss biopharmaceutical company’s shares surged in after-hours trading after it said the FDA approved its Optune Pax product.

Investors found the announced changes to the company's C-suite unsettling. On Tuesday, NovoCure announced that long-serving CEO Asaf Danziger is stepping down, effective Jan. 1, 2025. He will be ...